Michael Schmertzler sold $1.3M of PTCT
director at PTC THERAPEUTICS, INC.. 20,000 shares at an average of $67.49, traded Sep 16, 2026, filed Sep 18, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.3M at market
- 0Share of holdings soldSold 1.5% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001288952-26-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,994 | $66.58 | $199k | 1,313,600 | 24 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -7,006 | $67.35 | $472k | 1,306,594 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -9,624 | $67.83 | $653k | 1,296,970 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -376 | $68.45 | $26k | 1,296,594 | 24 d ago |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 15Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $2.9M 47,249 shares | -39% | |
| 0Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $137k 2,813 shares | -3% | |
| 12Weak | PTC THERAPEUTICS, INC. | Pierre Gravier CHIEF FINANCIAL OFFICER | $124k 2,516 shares | -3% | |
| 0Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $130k 2,812 shares | -3% | |
| 16Weak | PTC THERAPEUTICS, INC. | Matthew B. Klein CHIEF EXECUTIVE OFFICER | $137k 2,804 shares | -1% | |
| 1Weak | PTC THERAPEUTICS, INC. | Lee Scott Golden EVP & CHIEF MEDICAL OFFICER | $42k 897 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.